SCHEMBL19320910

SCHEMBL19320910

COCc1ccc2ccccc2c1C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.50
ALDH1A1 P00352 2/20 0.50
MEN1 O00255 1/20 0.50
CYP1A2 P05177 1/20 0.50
GLA P06280 1/20 0.50
HPGD P15428 1/20 0.50
CYP2C19 P33261 1/20 0.50
KMT2A Q03164 1/20 0.50
HSD17B10 Q99714 1/20 0.50
WDR5 P61964 1/20 0.43
ATM Q13315 1/20 0.43
METAP2 P50579 1/20 0.43
METAP1 P53582 1/20 0.43
NCEH1 Q6PIU2 1/20 0.42
TDP1 Q9NUW8 2/20 0.42
LDHA P00338 1/20 0.42
FDPS P14324 1/20 0.42
NR4A1 P22736 1/20 0.42
NR4A2 P43354 1/20 0.42
NR4A3 Q92570 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19320914 0.85 PARP10 (0.44) MEN1KMT2AATMNCEH1
SCHEMBL897607 0.84 KDM4E (0.55) KDM4EALDH1A1MEN1CYP1A2GLA
SCHEMBL19320915 0.84 KDM4E (0.43) KDM4EALDH1A1MEN1GLAKMT2A
SCHEMBL19325530 0.83 KDM4E (0.50) KDM4EALDH1A1MEN1CYP1A2GLA
Ammonia Solution, Strong SCHEMBL7720474 0.83 KDM4E (0.53) KDM4EALDH1A1MEN1CYP1A2GLA
Ammonia Solution, Strong SCHEMBL7720478 0.83 KDM4E (0.53) KDM4EALDH1A1MEN1CYP1A2GLA
SCHEMBL29913819 0.82 KDM4E (0.57) KDM4EALDH1A1MEN1CYP1A2GLA
SCHEMBL1696920 0.80 KDM4E (0.50) KDM4EALDH1A1MEN1CYP1A2GLA
SCHEMBL28145097 0.80 KDM4E (0.50) KDM4EALDH1A1MEN1CYP1A2GLA
SCHEMBL7798078 0.80 KDM4E (0.58) KDM4EALDH1A1GLAHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170253607-A1 LONG-ACTING HIV PROTEASE INHIBITOR SHIONOGI & CO., LTD. (JP) 2017-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170253607-A1 LONG-ACTING HIV PROTEASE INHIBITOR CPN1, HAT1, PRSS1 KDM4E 1195/4885ALDH1A1 4195/4885MEN1 4668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.